PKCζ, MMP‑2 and MMP‑9 expression in lung adenocarcinoma and association with a metastatic phenotype

Cai,Xiaoshan; Zhu,Hongguang; Li,Ying

doi:10.3892/mmr.2017.7634

PKCζ, MMP‑2 and MMP‑9 expression in lung adenocarcinoma and association with a metastatic phenotype

Authors:
- Xiaoshan Cai
- Hongguang Zhu
- Ying Li
View Affiliations

Affiliations: Department of Pathology, Second People's Hospital of Weifang, Weifang, Shandong 261041, P.R. China, Department of Dentistry, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
Published online on: September 26, 2017 https://doi.org/10.3892/mmr.2017.7634
Pages: 8301-8306

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate protein kinase C ζ type (PKCζ), matrix metalloproteinase (MMP)‑2 and MMP‑9 expression in lung adenocarcinoma and to define their association with in vitro invasion and metastatic capacity. PKCζ, MMP‑2 and MMP‑9 expression was assessed by immunohistochemistry in 110 cases of lung adenocarcinoma. PKCζ small interfering (si)RNA was transfected into A549 cells, and western blotting was used to confirm PKCζ‑knockdown in transfected cells and to measure MMP‑2 and MMP‑9 levels. A Transwell invasion assay was used to detect in vitro invasive capacity. The rates of positive PKCζ, MMP‑2 and MMP‑9 staining in lung adenocarcinoma tissues were 52.73, 55.45 and 61.82%, respectively. PKCζ expression was increased in malignant tissues compared with adjacent normal lung tissues and was associated with lymph node metastasis (P<0.05), although it was not associated with any other clinicopathological parameters, including sex, age, tumor size, smoking status or distant metastases (all P>0.05). PKCζ, MMP‑2 and MMP‑9 expression was markedly decreased in siPKCζ‑treated A549 cells, which exhibited a significantly decreased invasive capacity in the Transwell invasion assay (P<0.05). In conclusion, PKCζ promoted lung adenocarcinoma invasion and metastasis, and its expression was associated with MMP‑2 and MMP‑9 expression. PKCζ may be a potential target for gene therapy in lung adenocarcinoma.

View Figures

View References

1	Lu J, Wang W, Xu M, Li Y, Chen C and Wang X: A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. Semin Cancer Biol. 42:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wu J, Zhang B, Wu M, Li H, Niu R, Ying G and Zhang N: Screening of a PKC zeta-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis. Invest New Drugs. 28:268–275. 2010. View Article : Google Scholar : PubMed/NCBI
3	Butler AM, Scotti BML, Li S, Smith KE, Fields AP and Murray NR: Protein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mechanism. PLoS One. 8:e720612013. View Article : Google Scholar : PubMed/NCBI
4	Queisser MA, Dada LA, Deiss-Yehiely N, Angulo M, Zhou G, Kouri FM, Knab LM, Liu J, Stegh AH, DeCamp MM, et al: HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth. Am J Respir Crit Care Med. 190:688–698. 2014. View Article : Google Scholar : PubMed/NCBI
5	LaVallie ER, Chockalingam PS, Collins-Racie LA, Freeman BA, Keohan CC, Leitges M, Dorner AJ, Morris EA, Majumdar MK and Arai M: Protein kinase Czeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappaB by tumor necrosis factor and interleukin-1 in articular chondrocytes. J Biol Chem. 281:24124–24137. 2006. View Article : Google Scholar : PubMed/NCBI
6	Abdel-Halim M, Darwish SS, ElHady AK, Hoppstädter J, Abadi AH, Hartmann RW, Kiemer AK and Engel M: Pharmacological inhibition of protein kinase C (PKC)ζ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Eur J Pharm Sci. 93:405–409. 2016. View Article : Google Scholar : PubMed/NCBI
7	Diaz-Meco MT and Moscat J: The atypical PKCs in inflammation: NF-κB and beyond. Immunol Rev. 246:154–167. 2012. View Article : Google Scholar : PubMed/NCBI
8	Morin C, Fortin S and Rousseau E: Bronchial inflammation induced PKCζ over-expression: Involvement in mechanical properties of airway smooth muscle. Can J Physiol Pharmacol. 90:261–269. 2012. View Article : Google Scholar : PubMed/NCBI
9	Xu M, Wang HF and Zhang HZ: Expression of RECK and MMPs in hepatoblastoma and neuroblastoma and comparative analysis on the tumor metastasis. Asian Pac J Cancer Prev. 16:4007–4011. 2015. View Article : Google Scholar : PubMed/NCBI
10	Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM and Al-Qahtani MH: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 34:1355–1366. 2014.PubMed/NCBI
11	Parks WC, Wilson CL and López-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 4:617–629. 2004. View Article : Google Scholar : PubMed/NCBI
12	Babykutty S, Suboj P, Srinivas P, Nair AS, Chandramohan K and Gopala S: Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis. 29:471–492. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kim HIe, Lee HS, Kim TH, Lee JS, Lee ST and Lee SJ: Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells. Oncotarget. 6:42905–42922. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S and Kawai T: Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 35:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zhang F, Dong W, Zeng W, Zhang L, Zhang C, Qiu Y, Wang L, Yin X, Zhang C and Liang W: Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation. Breast Cancer Res. 18:382016. View Article : Google Scholar : PubMed/NCBI
16	Paul A, Danley M, Saha B, Tawfik O and Paul S: PKCζ Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NFκB-p65. Sci Rep. 5:125202015. View Article : Google Scholar : PubMed/NCBI
17	McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
18	S LH Yang, Li W YL, Ni M ZL and Yin CaZB: Expression and correlation of PKCζ, MMP-2 and MMP-9 in breast cancer. Chin J Clin Exp Pathol. 30:958–962. 2014.
19	Mirsadraee S, Oswal D, Alizadeh Y, Caulo A and van Beek E Jr: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
20	Rajagopalan S, Moyle MW, Joosten I and Long EO: DNA-PKcs controls an endosomal signaling pathway for a proinflammatory response by natural killer cells. Sci Signal. 3:ra142010. View Article : Google Scholar : PubMed/NCBI
21	Lim PS, Sutton CR and Rao S: Protein kinase C in the immune system: From signalling to chromatin regulation. Immunology. 146:508–522. 2015. View Article : Google Scholar : PubMed/NCBI
22	Fields AP and Regala RP: Protein kinase C iota: Human oncogene, prognostic marker and therapeutic target. Pharmacol Res. 55:487–497. 2007. View Article : Google Scholar : PubMed/NCBI
23	Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, et al: Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 160:489–502. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ and Zhang N: Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 65:1433–1441. 2005. View Article : Google Scholar : PubMed/NCBI
25	Ma NZF, Guo HZX, Cao SNR and Zhang N: Correlation between PKCζ expression and invasion, metastasis and prognosis of adenoearcinoma of the lung. Chin J Clin Oncol. 37:557–560. 2010.
26	Kuo HY, Huang YS, Tseng CH, Chen YC, Chang YW, Shih HM and Wu CW: PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2. Cell Cycle. 13:3132–3142. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yu Y, Ding Z, Jian H, Shen L, Zhu L and Lu S: Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. Cancer Med. 5:2323–2331. 2016. View Article : Google Scholar : PubMed/NCBI
28	King PT: Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 4:682015. View Article : Google Scholar : PubMed/NCBI
29	González-Arriaga P, Pascual T, García-Alvarez A, Fernández-Somoano A, López-Cima MF and Tardón A: Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 12:1212012. View Article : Google Scholar : PubMed/NCBI